Strategy to Inhibit TGF-beta in Liver Disease
A broad spectrum of scientific and technological capacities is needed to accomplish the goal of discovering drugs and treatment modalities for chronic liver disease (CLD) and hepatocellular carcinoma (HCC). The IT-LIVER partners from universities and pharmaceutical companies bring together their expertise to provide a comprehensive research and training program in an integrative way with the goal to combat CLD by (i) unravelling the molecular and cellular complexities of “Transforming Growth Factor” (TGF)-beta responses in CLD progression and (ii) rationally designing and discovering CLD/HCC drugs, drug delivery systems and CLD/HCC treatment modalities.
Thus, this Marie Curie project provides a multidisciplinary and intersectorial Research Training Program for talented young researchers to prepare them for leading roles in CLD/HCC research and drug discovery in European industry and academia.
MedUni Vienna Researchers
The Medical University of Vienna is project partner under the leadership of Ao. Prof. Dr. Wolfgang Mikulits, University Departmen of Internal Medicine I, Institute of Cancer Research.
Project coworker: Petra Koudelková (PhD student)
Project coordinatorIn: Dr.in Isabel Fabregat, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spanien.
Project partners: 11
|Topic||FP7-PEOPLE-2012-ITN, Initial Training Networks|
|Project Duration||Okt. 2012 bis Sept. 2016|
|Funding Volume, total||€ 3.312.185|
|Funding Volume, Medical University of Vienna||€ 257.801|